IAGL
ANTX icon

Innovative Advisory Group, LLC’s AN2 Therapeutics ANTX Stock Holding History

Innovative Advisory Group, LLC’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,170
Closed -$1.33K – 44
2025
Q4 		$1.33K Hold
1,170
– – ﹤0.01% 211
2025
Q3 		$1.49K Hold
1,170
– – ﹤0.01% 208
2025
Q2 		$1.24K Hold
1,170
– – ﹤0.01% 208
2025
Q1 		$1.59K Hold
1,170
– – ﹤0.01% 174
2024
Q4 		$1.61K Buy
+1,170
New +$1.42K ﹤0.01% 170

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Innovative Advisory Group, LLC's ANTX Position: Q1 2026 in Review

Innovative Advisory Group, LLC sold out of AN2 Therapeutics (ANTX) in Q1 2026, closing a stake of 1,170 shares — an estimated $1.33K sold.

Innovative Advisory Group, LLC first reported a position in ANTX in Q4 2024 and held it in 5 quarters. The position peaked at $1.61K in Q4 2024. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Innovative Advisory Group, LLC reported no remaining AN2 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Innovative Advisory Group, LLC sold 1,170 AN2 Therapeutics shares in Q1 2026, an estimated $1.33K.
  • Innovative Advisory Group, LLC first reported a position in AN2 Therapeutics in Q4 2024 and held it in 5 quarters.
  • Innovative Advisory Group, LLC's AN2 Therapeutics position peaked at $1.61K in Q4 2024.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Innovative Advisory Group, LLC's 13F filing for Q1 2026, filed 22 Sep 2026.